Publication|Articles|May 28, 2026
Supplements and Featured Publications
- Myelofibrosis Treatment: Health Economic Considerations
Myelofibrosis Treatment: Health Economic Considerations
This Clinical Brief is intended for payers, formulary committee members, drug selection panels, and other similar multidisciplinary individuals or entities. It contains health care economic information to aid in the selection of drugs for coverage or reimbursement. It is not intended for health care providers making individual prescribing decisions or for consumers.
Advertisement
This Clinical Brief was sponsored by Incyte.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
ACP Names Semaglutide, Tirzepatide as First-Line Pharmacotherapy for Obesity
2
CMS Proposes Permanent Rules for Medicare Drug Price Negotiation
3
Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies
4
AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike
5
